The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome

Clinical Endocrinology

Volumn 64, Issue 5, 2006, Pages 519-522

  Mullan, Karen R ^a   Leslie, Hilary ^a   McCance, David R ^a   Sheridan, Brian ^a   Atkinson, A Brew ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ADRENALECTOMY; ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CUSHING DISEASE; DOSE RESPONSE; DRUG EFFECT; HUMAN; NELSON SYNDROME; PRIORITY JOURNAL;

ADRENALECTOMY; ADRENOCORTICOTROPIC HORMONE; ADULT; DRUG ADMINISTRATION SCHEDULE; HUMANS; MIDDLE AGED; NELSON SYNDROME; PITUITARY ACTH HYPERSECRETION; PPAR GAMMA; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT FAILURE;

EID: 33645986967     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02501.x     Document Type: Article

References (8)

1. McCance D.R. Russell C.F. Kennedy T.L. Hadden D.R. Kennedy L. Atkinson A.B. 1993 Bilateral adrenalectomy: low mortality and morbidity in Cushing's disease. Clinical Endocrinology 39 315 321.
2. Jenkins P.J. Trainer P.J. Plowman P.N. Shand W.S. Grossman A.B. Wass J.A. Besser G.M. 1995 The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 80 165 171.
3. Heaney A.P. Fernando M. Yong W.H. Melmed S. 2002 Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nature Medicine 8 1281 1287.
4. Munir A. Song F. Ince P. Ross R. Newell-Price J. A pilot study of prolonged high-dose rosiglitazone therapy (12 mg/day) in Nelson's syndrome. Abstract OC 24 195th Meeting of the Society for Endocrinology joint with Diabetes UK and the Growth factor Group, Royal College of Physicians, London, UK.
5. Hull S.S. Sheridan B. Atkinson A.B. 2005 Preoperative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clinical Endocrinology 62 259 261.
6. Suri D. Weiss R.E. 2005 Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. Journal of Clinical Endocrinology and Metabolism 90 1340 1346.
7. Ambrosi B. Dall'Asta C. Cannavo S. Libe R. Vigo T. Epaminonda P. Chiodini I. Ferrero S. Trimarchi F. Arosio M. Beck-Peccoz P. 2004 Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. European Journal of Endocrinology 151 173 178.
8. Heaney A.P. 2003 ) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (Cushing's disease). Conference Proceeding 85th Annual Meeting 2003, The Endocrine Society, Philadelphia, PA, USA, June 19-22 2003, OR7-4.